POTENTIATION OF PIRARUBICIN CYTOTOXICITY BY DIPYRIDAMOLE IN DOXORUBICIN-RESISTANT MOUSE P388 LEUKEMIA-CELLS

被引:0
|
作者
FURUSAWA, S
FUJIMURA, T
KAWAUCHI, H
SASAKI, K
TAKAYANAGI, Y
机构
关键词
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The activity of dipyridamole and its possible mechanisms which reverse the resistance to pirarubicin were studied in a P388 mouse leukemia cell lines. Dipyridamole alone was minimally cytotoxic in both of the doxorubicin-resistant cell line (P388/DOX) and the sensitive parent cell line (P388/S), but reversed pirarubicin-resistance in a dose-related manner in P388/DOX cells. A similar dose-response relationship was observed for dipyridamole by increasing net intracellular pirarubicin accumulation. The increase was a result of secondary blocking of enhanced pirarubicin efflux from P388/DOX cells. In contrast, dipyridamole did not affect cytotoxicity and transport in the drug-sensitive cell line. It is suggested that dipyridamole is a useful drug for modulation of the multidrug-resistance of cells.
引用
收藏
页码:321 / 336
页数:16
相关论文
共 50 条
  • [1] AUGMENTATION OF PIRARUBICIN CYTOTOXICITY BY CHLORPROMAZINE IN DOXORUBICIN-RESISTANT MOUSE P388 LEUKEMIA-CELLS
    SHIBATA, H
    SANO, F
    FURUSAWA, S
    KAWAUCHI, H
    SASAKI, K
    TAKAYANAGI, Y
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1990, 110 (09): : 678 - 681
  • [2] RESTORATION OF DOXORUBICIN RESPONSIVENESS IN DOXORUBICIN-RESISTANT P388 MURINE LEUKEMIA-CELLS
    RAMU, A
    SPANIER, R
    RAHAMIMOFF, H
    FUKS, Z
    BRITISH JOURNAL OF CANCER, 1984, 50 (04) : 501 - 507
  • [3] CHARACTERIZATION OF CELLULAR LIPIDS IN DOXORUBICIN-SENSITIVE AND DOXORUBICIN-RESISTANT P388 MOUSE LEUKEMIA-CELLS
    HOLLERAN, WM
    DEGREGORIO, MW
    GANAPATHI, R
    WILBUR, JR
    MACHER, BA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1986, 17 (01) : 11 - 15
  • [4] POTENTIATION OF ANTITUMOR-ACTIVITY OF PIRARUBICIN BY CHLORPROMAZINE IN MICE BEARING DOXORUBICIN-RESISTANT P388 LEUKEMIA
    SHIBATA, H
    MAEKAWA, I
    FURUSAWA, S
    KAWAUCHI, H
    TAKAYANAGI, Y
    SASAKI, K
    RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, 1990, 70 (03): : 359 - 362
  • [5] RESTORATION OF DOXORUBICIN RESPONSIVENESS IN DOXORUBICIN-RESISTANT P388 MURINE LEUKEMIA-CELLS BY DIPYRONE
    CHITNIS, MP
    KAMATH, NS
    ONCOLOGY, 1987, 44 (01) : 47 - 50
  • [6] BETA-ADRENERGIC INFLUENCES ON DOXORUBICIN-SENSITIVE OR DOXORUBICIN-RESISTANT P388 LEUKEMIA-CELLS
    DAMICO, C
    CRESCIMANNO, M
    ARMATA, MG
    LEONARDI, V
    PALAZZOADRIANO, M
    DALESSANDRO, N
    ANTICANCER RESEARCH, 1992, 12 (6B) : 2253 - 2256
  • [7] OXYGEN RADICAL DETOXIFICATION ENZYMES IN DOXORUBICIN-SENSITIVE AND DOXORUBICIN-RESISTANT P388 MURINE LEUKEMIA-CELLS
    RAMU, A
    COHEN, L
    GLAUBIGER, D
    CANCER RESEARCH, 1984, 44 (05) : 1976 - 1980
  • [8] MECHANISM OF ACQUIRED-RESISTANCE TO METHOTREXATE IN P388 MURINE LEUKEMIA-CELLS AND IN THEIR DOXORUBICIN-RESISTANT SUBLINE
    RAMU, N
    RAMU, A
    COLE, DE
    BALIS, FM
    POPLACK, DG
    POLLARD, HB
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1988, 24 (9-10): : 477 - 482
  • [9] COMPARISON OF DOXORUBICIN-INDUCED DNA DAMAGE IN DOXORUBICIN-SENSITIVE AND DOXORUBICIN-RESISTANT P388 MURINE LEUKEMIA-CELLS
    CAPRANICO, G
    DASDIA, T
    ZUNINO, F
    INTERNATIONAL JOURNAL OF CANCER, 1986, 37 (02) : 227 - 231
  • [10] BIOCHEMICAL AND MORPHOLOGICAL-STUDIES IN P388 SENSITIVE AND DOXORUBICIN RESISTANT (P388 DX) LEUKEMIA-CELLS
    FACCHINETTI, T
    MALISANO, G
    SALARDI, S
    GERONI, C
    BELLINI, O
    ESPOSITO, G
    GIULIANI, FC
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 343 - 343